185株对青霉素敏感和耐药的肺炎球菌对新型口服青霉烯类药物WY-49605（SUN/SY 5555）的体外药敏情况，并与它们对青霉素G、阿莫西林、阿莫西林-克拉维酸、头孢克肟、头孢克洛、头孢泊肟、头孢呋辛和头孢地尼的药敏情况进行比较。
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
作者信息
Spangler S K, Jacobs M R, Appelbaum P C
机构信息
Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033.
出版信息
Antimicrob Agents Chemother. 1994 Dec;38(12):2902-4. doi: 10.1128/AAC.38.12.2902.
Abstract
In vitro susceptibility of 185 penicillin-susceptible and -resistant pneumococci to WY-49605, a new oral penem, was compared with susceptibility to penicillin G, amoxicillin with and without clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. WY-49605 yielded MICs for 50 and 90% of the strains tested (MIC50 and MIC90, respectively) of 0.03 and 0.06, 0.125 and 0.5, and 0.5 and 1.0 micrograms/ml, respectively, against penicillin-susceptible, intermediately resistant, and fully resistant strains, respectively. The MIC50 and MIC90 for both amoxicillin and amoxicillin-clavulanate were identical and approximately 1 doubling dilution higher than those for WY-49605 and were < or = 0.06 and 0.125, 0.25 and 1.0, and 1.0 and 1.0 micrograms/ml, respectively. Cephalosporin MIC90s were all significantly higher than those of the latter three compounds for intermediately resistant and fully resistant strains.
摘要
将185株对青霉素敏感和耐药的肺炎球菌对新型口服青霉烯类药物WY - 49605的体外敏感性，与对青霉素G、含和不含克拉维酸的阿莫西林、头孢克肟、头孢克洛、头孢泊肟酯、头孢呋辛和头孢地尼的敏感性进行比较。WY - 49605对青霉素敏感、中度耐药和完全耐药菌株的50%和90%受试菌株（分别为MIC50和MIC90）的MIC值分别为0.03和0.06、0.125和0.5、0.5和1.0微克/毫升。阿莫西林和阿莫西林 - 克拉维酸的MIC50和MIC90相同，比WY - 49605的MIC值高约1倍稀释度，分别为≤0.06和0.125、0.25和1.0、1.0和1.0微克/毫升。对于中度耐药和完全耐药菌株，头孢菌素的MIC90均显著高于后三种化合物。
相似文献
1
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
Antimicrob Agents Chemother. 1994 Dec;38(12):2902-4. doi: 10.1128/AAC.38.12.2902.
2
In vitro susceptibility of 90 penicillin-susceptible and -resistant pneumococci to penicillin G, amoxicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, cefixime and imipenem.
Folia Microbiol (Praha). 1998;43(1):68-70. doi: 10.1007/BF02815546.
3
Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Antimicrob Agents Chemother. 1994 Nov;38(11):2599-604. doi: 10.1128/AAC.38.11.2599.
4
Comparative in-vitro activity of cefdinir against multiresistant Haemophilus influenzae.
J Antimicrob Chemother. 1994 Jul;34(1):161-4. doi: 10.1093/jac/34.1.161.
5
Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Infection. 1991 Sep-Oct;19(5):353-62. doi: 10.1007/BF01645369.
6
Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.
Antimicrob Agents Chemother. 1995 Jul;39(7):1591-5. doi: 10.1128/AAC.39.7.1591.
7
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
J Antimicrob Chemother. 1998 Mar;41(3):381-5. doi: 10.1093/jac/41.3.381.
8
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.
Antimicrob Agents Chemother. 1988 May;32(5):671-7. doi: 10.1128/AAC.32.5.671.
9
Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.
Antimicrob Agents Chemother. 1995 Jul;39(7):1499-504. doi: 10.1128/AAC.39.7.1499.
10
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.
Diagn Microbiol Infect Dis. 1986 Jul;5(2):151-62. doi: 10.1016/0732-8893(86)90117-3.
引用本文的文献
1
Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
Drugs. 2004;64(13):1433-64. doi: 10.2165/00003495-200464130-00004.
2
Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 250 invasive Streptococcus pneumoniae isolates from France.
Eur J Clin Microbiol Infect Dis. 2003 Sep;22(9):561-5. doi: 10.1007/s10096-003-0990-7. Epub 2003 Aug 27.
3
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Antimicrob Agents Chemother. 2002 Feb;46(2):550-5. doi: 10.1128/AAC.46.2.550-555.2002.
4
Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.
Curr Infect Dis Rep. 1999 Apr;1(1):13-21. doi: 10.1007/s11908-999-0004-8.
5
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
Antimicrob Agents Chemother. 1998 Mar;42(3):624-30. doi: 10.1128/AAC.42.3.624.
6
Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.
Antimicrob Agents Chemother. 1997 Oct;41(10):2173-6. doi: 10.1128/AAC.41.10.2173.
7
Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.
Antimicrob Agents Chemother. 1997 Jun;41(6):1260-8. doi: 10.1128/AAC.41.6.1260.
8
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.
Antimicrob Agents Chemother. 1997 May;41(5):1033-6. doi: 10.1128/AAC.41.5.1033.
9
MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.
Antimicrob Agents Chemother. 1997 Jan;41(1):148-55. doi: 10.1128/AAC.41.1.148.
10
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
Antimicrob Agents Chemother. 1996 Feb;40(2):481-4. doi: 10.1128/AAC.40.2.481.
本文引用的文献
1
Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.
J Antibiot (Tokyo). 1989 Jun;42(6):977-88. doi: 10.7164/antibiotics.42.977.
2
Susceptibility of anaerobic bacteria to ALP 201.
Antimicrob Agents Chemother. 1989 Dec;33(12):2137-9. doi: 10.1128/AAC.33.12.2137.
3
Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):919-24. doi: 10.1007/BF01963784.
4
Comparative antibacterial activity of the penem ALP 201.
Chemotherapy. 1991;37(6):413-9. doi: 10.1159/000238888.
5
Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).
Clin Infect Dis. 1992 Jul;15(1):99-105. doi: 10.1093/clinids/15.1.99.
6
Antimicrobial resistance in Streptococcus pneumoniae: an overview.
Clin Infect Dis. 1992 Jul;15(1):77-83. doi: 10.1093/clinids/15.1.77.
7
Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.
Clin Infect Dis. 1992 Jul;15(1):119-27. doi: 10.1093/clinids/15.1.119.
8
Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.
J Antimicrob Chemother. 1992 Sep;30(3):279-88. doi: 10.1093/jac/30.3.279.
Zotero 插件